Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0216)
Name
Tectoridin
Synonyms
Tectoridin; 611-40-5; Shekanin; 4',5-Dihydro-6-methoxy-7-(o-glucoside)isoflavone; BRN 0068384; CHEBI:9428; 968X515NZH; 5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; 5-Hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 7-(beta-D-Glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-; Tectoridin (7CI,8CI); UNII-968X515NZH; 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-; TECTORIDIN [MI]; 4-18-00-03312 (Beilstein Handbook Reference); SCHEMBL241734; CHEMBL520214; TECTORIGENIN-7-GLUCOSIDE; DTXSID70209982; CNOURESJATUGPN-UDEBZQQRSA-N; HY-N0791; BDBM50540975; MFCD01662715; AKOS015897164; CCG-269367; Tectorigenin 7-O-beta-D-glucopyranoside; 5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; BS-17204; CS-0009803; S3818; T3724; A868796; TECTORIGENIN 7-O-.BETA.-D-GLUCOPYRANOSIDE; Q-100704; Q10860610; 5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-1-benzopyran-7-yl beta-D-glucopyranoside

    Click to Show/Hide
Structure
Formula
C22H22O11
IUPAC Name
5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
Canonical SMILES
COC1=C(C=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)OC4C(C(C(C(O4)CO)O)O)O
InChI
InChI=1S/C22H22O11/c1-30-21-13(32-22-20(29)19(28)17(26)14(7-23)33-22)6-12-15(18(21)27)16(25)11(8-31-12)9-2-4-10(24)5-3-9/h2-6,8,14,17,19-20,22-24,26-29H,7H2,1H3/t14-,17-,19+,20-,22-/m1/s1
InChIKey
CNOURESJATUGPN-UDEBZQQRSA-N
PubChem CID
5281810
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Lung cancer ICD-11: 2C25
 Disease Info 
Responsed Regulator Serine/threonine-protein kinase PLK1 (PLK1) Driver
 Regulator Info 
Pathway Response Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
In Vitro Model A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
Response regulation Tectoridin synergized with PLK1 inhibitor to suppress autophagy and ferroptosis but promoted caspase-3-mediated apoptosis in A549 (Lung adenocarcinoma) cells. Our findings highlight a potential drug target and the combination therapy strategy of PLK1 inhibitor and tectoridin for LUAD patients. In vitro experiments, we confirmed that tectoridin could inhibit the expression of PLK1.
References
Ref 1 Tectoridin and PLK1 inhibitor synergistically promote the apoptosis of lung adenocarcinoma cells: Bioinformatic analysis of TCGA and TCMSP. Naunyn Schmiedebergs Arch Pharmacol. 2023 Oct;396(10):2417-2426. doi: 10.1007/s00210-023-02460-2. Epub 2023 Apr 4.